证券代码：688575 证券简称：亚辉龙 公告编号：2024-020 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 截至2023年12月31日，募集资金账户余额为5,889,514.08元(包含累计收到的理财 收益和银行存款利息扣除银行手续费等的净额)。此外，公司使用闲置募集资金暂时 补充流动资金金额100,000,000.00元。 4 (一)实际募集资金金额及资金到账时间 根据中国证券监督管理委员会于2021年3月9日核发的《关于同意深圳市亚辉龙 生物科技股份有限公司首次公开发行股票注册的批复》（证监许可[2021]755号）， 公司向社会公众公开发行人民币普通股（A股）4,100万股（每股面值人民币1元）， 并于2021年5月17日在上海证券交易所科创板上市（以下简称"本次发行"）。本次发 行的发行价格为14.80元/股，本次发行募集资金总额606,800,000.00元，扣除公司不 含增值税的保荐及承销费以及其他发行费用后募集资金净额为541,334,440.75元。大 华会计师事务所（特殊普通合伙）已于2021年 ...

证券代码：688575 证券简称：亚辉龙 公告编号：2024-023 深圳市亚辉龙生物科技股份有限公司 关于部分募投项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 深圳市亚辉龙生物科技股份有限公司（以下简称"公司"）于 2024 年 4 月 18 日召开第三届董事会第二十一次会议、第三届监事会第二十次会议，审议通过了《关 于部分募投项目延期的议案》，同意公司将首次公开发行募集资金投资项目之"研 发中心升级及产能扩充项目"（以下简称"募投项目"）达到预定可使用状态的日 期延长至 2025 年 6 月 30 日。本次延期是公司根据项目实施的实际情况做出的调整 决定，仅涉及因增加投资金额导致项目建设完成时间的变化，未改变募投项目的实 施主体，不会对该募投项目的实施造成实质性影响。保荐机构中信证券股份有限公 司（以下简称"保荐机构"）对本事项出具了无异议的核查意见。本事项无需提请 公司股东大会审议，现将有关情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2021 年 ...

深圳市亚辉龙生物科技股份有限公司 2023 年度独立董事述职报告 作为深圳市亚辉龙生物科技股份有限公司（以下简称"公司"）的独立董事， 根据《上市公司独立董事管理办法》《上海证券交易所科创板股票上市规则》《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《公司章程》 《公司独立董事工作细则》等有关规定，本人认真行使法规所赋予的权利，及时 了解公司的经营管理信息，全面关注公司的发展状况，积极出席公司召开的相关 会议，对董事会审议事项进行了审核，积极发挥独立董事的独立作用，维护公司 及全体股东的利益。现将 2023 年度工作情况报告如下： 一、独立董事的基本情况 （一）独立董事人员情况 公司董事会由 7 名董事组成，其中独立董事 3 人，占董事会人数三分之一， 且至少 1 人为会计专业人士，符合相关法律法规及公司制度的规定。报告期内， 公司独立董事成员包括章顺文先生（已离任）、刘登明先生、李学金先生、石春 茂先生（新任）。其中，章顺文先生、石春茂先生为会计专业人士。 （二）个人工作履历、专业背景及兼职情况 本人石春茂，1970 年生，中国国籍，无境外永久居留权，会计学博士，注 册会计师。曾任武汉 ...

Market Overview - The global in vitro diagnostics market is expected to exceed $106 billion in 2023, with China's market size surpassing 170 billion RMB in 2022, reflecting a year-on-year growth of over 30%[22]. - The market for in vitro diagnostics is expected to continue its rapid growth, driven by increasing health awareness and demand for diagnostic services among the population[22]. - The domestic market is transitioning from traditional enzyme-linked immunoassay to chemiluminescence immunoassay, indicating a significant growth opportunity in secondary and primary healthcare institutions[11]. - The domestic market for chemical luminescence diagnostics is expanding as local companies improve product quality to compete with international leaders like Roche and Abbott, who currently dominate the market[69]. - The potential patient population for autoimmune diseases in China is significant, with only about 20 million confirmed cases compared to an estimated 14.7 to 23.5 million in the United States, indicating a large market opportunity[71]. Company Positioning and Strategy - The company specializes in in vitro diagnostic products, primarily focusing on chemiluminescence immunoassay technology, which has become the dominant method in major hospitals[11]. - The company adopts a sales model primarily based on distribution, with direct sales to key clients in specific regions, enhancing market penetration[21]. - The company is positioned in the medical manufacturing sector, specifically in the manufacturing of medical instruments and devices, classified under the pharmaceutical manufacturing industry[21]. - The company emphasizes the importance of technological innovation and product development capabilities to maintain competitiveness in the rapidly evolving diagnostics market[22]. - The company is focusing on the development of high-quality, cost-effective diagnostic products suitable for primary healthcare institutions, which lack specialized testing facilities[81]. Product Development and Innovation - Chemiluminescence immunoassay technology offers advantages such as high sensitivity, stable results, and ease of use, driving its adoption in clinical settings[11]. - The company has developed a fully automated immunoassay system based on magnetic microparticle acridinium ester chemiluminescence technology, breaking the foreign monopoly in this field[26]. - The company launched 16 new testing reagent products during the reporting period, with 14 chemiluminescence detection projects and 1 immunoblotting detection project receiving domestic registration certificates[28]. - The company has developed a high-throughput fully automated biochemical immuno-integrated machine and other intelligent product solutions to meet diverse needs of medical institutions[55]. - The company is actively developing new instruments and reagents, including a microfluidic in vitro diagnostic technology platform and a molecular diagnostic technology platform, to enhance its product line and innovation capabilities[88]. Financial Performance - The company achieved a gross margin of 56.57% for its main business, an increase of 2.92 percentage points from the previous year, with a non-COVID self-operated business gross margin of 70.00%[39]. - The company's annual revenue for 2023 decreased by 48.42% compared to the previous year, primarily due to a significant decline in revenue from COVID-related business[129]. - The net profit attributable to shareholders was 355.01 million CNY, a decrease of 64.92% year-on-year[55]. - The company's total revenue for 2023 was CNY 2,053.10 million, a decrease of 48.42% year-on-year, primarily due to a 87.46% decline in COVID-related business revenue[154]. - Non-COVID business revenue reached CNY 1,711.25 million, an increase of 36.30% year-on-year, with domestic non-COVID self-operated business revenue growing by 47.80% to CNY 1,174.16 million[154]. Research and Development - R&D investment amounted to 325.35 million yuan, a year-on-year increase of 30.04%, with 125.31 million yuan allocated to microfluidics, sequencing, and other advanced technologies[39]. - The company achieved a total R&D investment of approximately ¥325.35 million in the reporting period, representing a 30.04% increase compared to the previous year, with R&D expenses accounting for 15.85% of operating revenue, an increase of 9.57 percentage points[93]. - The company has completed the acceptance of 80 self-developed antigen/antibody raw materials during the reporting period, which are key materials for in vitro diagnostic reagents[96]. - The company is in the process of developing various projects, including a gene sequencing project with a total investment of ¥20 million, which has seen an investment of ¥5.54 million so far[96]. - The company is committed to continuous research and development, having established a strong foundation in various diagnostic technologies over the past decade[73]. Market Expansion and Collaborations - The company has established a service network in India and Nepal, and is preparing to set up networks in the CIS and Latin America regions[43]. - The company signed a strategic cooperation agreement with MBL to enhance collaboration in immunology, cardiology, and diabetes diagnostics for the Japanese market[43]. - The company is actively expanding its product line by developing more high-quality reagents based on market demand and technological resources[100]. - The company is exploring strategic acquisitions to enhance its product portfolio, with a budget of 500 million allocated for potential deals[197]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[197]. Regulatory and Certification Achievements - The company has received 89 IVDR CE certifications during the reporting period, bringing the total to 174 certifications[28]. - The company obtained 92 new domestic medical device product registrations and 89 new EU CE certifications during the reporting period, including 62 IVDR class B and 27 IVDR class C certifications[90]. - The company has achieved recognition as a national "specialized and innovative" small giant enterprise, enhancing its credibility in the industry[74]. - The company has 193 domestic and 21 foreign authorized patents, including 89 invention patents and 52 software copyrights[105]. - The company has developed 163 chemical luminescence diagnostic projects and 80 biochemical diagnostic projects that have received domestic and international registration certificates, including 53 projects for chemical luminescence autoimmune diagnostics[74]. Operational Efficiency and Governance - The company implemented 12 automated devices in 2023, significantly improving production efficiency and reducing reagent manufacturing costs[175]. - The board of directors unanimously approved all proposals related to independent director nominations, ensuring strong governance[196]. - The audit committee reported no significant risks identified during the review period, indicating a stable financial position[198]. - The company has no significant risks that could materially affect its operations during the reporting period[113]. - The company plans to implement a new compensation structure aimed at improving employee retention and performance, with a focus on aligning incentives with long-term growth[197].

Financial Performance - The company's operating revenue for Q1 2024 was CNY 431,322,575.83, representing a decrease of 34.65% compared to the same period last year[15]. - The net profit attributable to shareholders of the listed company was CNY 66,034,591.72, down 18.72% year-on-year[15]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 57,166,617.62, a decrease of 31.29% compared to the previous year[15]. - In Q1 2024, the company achieved operating revenue of RMB 431.32 million, a decrease of 34.65% year-on-year; net profit attributable to shareholders was RMB 66.03 million, down 18.72% year-on-year[26]. - Net profit attributable to shareholders of the listed company fell by 18.71%, primarily due to a decline in COVID-related business revenue[42]. - The net profit excluding non-recurring gains and losses decreased by 31.28%[42]. - The total profit for the period was 63,495,903.50, compared to 83,360,612.59 in the previous year[57]. - The net profit for the period was 55,939,738.75, down from 67,743,836.57 in the previous year[57]. - Basic earnings per share for the period were 0.12, compared to 0.14 in the previous year[41]. - The company's total operating profit for Q1 2024 was RMB 64,004,346.42, down from RMB 84,505,378.51 in Q1 2023[63]. Assets and Equity - The total assets at the end of the reporting period were CNY 3,862,261,571.05, an increase of 1.48% from the end of the previous year[17]. - The equity attributable to shareholders of the listed company was CNY 2,626,037,203.18, reflecting a 2.59% increase from the previous year[17]. - The total liabilities and shareholders' equity amounted to 3,862,261,571.05, compared to 3,806,083,365.13 in the previous year[36]. - The company's total equity attributable to shareholders was 2,626,037,203.18, an increase from 2,559,840,879.62 in the previous year[36]. - The total assets of the company as of March 31, 2024, amounted to RMB 3.86 billion, compared to RMB 3.81 billion at the end of 2023[35]. Cash Flow - The net cash flow from operating activities was CNY 70,007,095.70[17]. - Net cash flow from operating activities for Q1 2024 was RMB 70,007,095.70, a significant improvement from a negative RMB 361,704,844.36 in Q1 2023[65]. - Cash and cash equivalents at the end of Q1 2024 were RMB 502,908,916.24, compared to RMB 726,160,578.88 at the end of Q1 2023[66]. - The company reported a net loss from investments of RMB 5,549,342.37 in Q1 2024, contrasting with a gain of RMB 1,718,670.02 in Q1 2023[63]. - Total cash inflow from investment activities in Q1 2024 was RMB 62,563,900.46, compared to RMB 50,247,072.08 in Q1 2023[66]. - The company’s financing activities generated a net cash inflow of RMB 35,735,837.11 in Q1 2024, compared to a net outflow of RMB 11,698,643.72 in Q1 2023[66]. Research and Development - Research and development expenses totaled CNY 84,553,036.69, which is 19.60% of operating revenue, an increase of 10.18 percentage points year-on-year[17]. - Research and development expenses increased to RMB 83,803,207.87 in Q1 2024, up 40.4% from RMB 59,637,893.36 in Q1 2023[63]. Business Operations - Non-COVID self-operated business revenue reached RMB 341.68 million in Q1 2024, representing a year-on-year growth of 43.33%[27]. - Domestic non-COVID self-operated business revenue was RMB 302.99 million, up 44.10% year-on-year, with domestic self-produced chemiluminescence business revenue at RMB 273.69 million, a 47.73% increase[28]. - As of March 31, 2024, the company’s products covered over 5,440 domestic terminal medical institutions, an increase of over 150 from the end of 2023, with coverage in over 1,180 tertiary hospitals[29]. - In Q1 2024, the company installed 418 new self-produced chemiluminescence analyzers, with 271 units in the domestic market and 147 units overseas[48]. - The company has obtained 157 domestic medical device registration certificates for chemiluminescence reagents, enhancing its product offerings in reproductive health diagnostics[48]. Operating Costs - Total operating costs for Q1 2024 were RMB 375,490,702.93, down 34.0% from RMB 567,935,779.01 in Q1 2023[63]. - Sales revenue from goods and services received cash of RMB 449,418,964.34 in Q1 2024, an increase from RMB 403,448,280.82 in Q1 2023[65].

深圳市亚辉龙生物科技股份有限公司 审计报告 大华审字[2024]0011020514 号 大华会计师事务所(特殊普通合伙) Da Hua Certified Public Accountants (Special General Partnership) 您可使用手机"扫一扫"或进入"注册贵元证明该审计报告是否由具有拟业许可的会计师事务所出具。 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://agc.mof.gov.go）"进行查整 深圳市亚辉龙生物科技股份有限公司 审计报告及财务报表 (2023年1月1日至2023年12月31日止) | | 目 录 | 页 次 | | --- | --- | --- | | 5 | 审计报告 | 1-8 | | í í | 已审财务报表 | | | | 合并资产负债表 | 1-2 | | | 合并利润表 | 3 | | | 合并现金流量表 | 4 | | | 合并股东权益变动表 | 5-6 | | | 母公司资产负债表 | 7-8 | | | 母公司利润表 | 9 | | | 母公司现金流量表 | 10 | | | 母公司股东权益变动表 | 11-1 ...

中信证券股份有限公司 关于深圳市亚辉龙生物科技股份有限公司 2023 年度募集资金存放与使用实际情况的专项核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）为深圳市亚辉 龙生物科技股份有限公司（以下简称"公司"、"亚辉龙"）首次公开发行股票并上 市的保荐机构。根据《证券发行上市保荐业务管理办法》、《上市公司监管指引 第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》、《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》、《上海证券 交易所科创板股票上市规则（2023 年 8 月修订）》，对亚辉龙 2023 年度募集资 金的存放和使用实际情况进行了专项核查，核查情况及核查意见如下： 一、募集资金基本情况 （一）实际募集资金金额及资金到账时间 根据中国证券监督管理委员会于 2021 年 3 月 9 日核发的《关于同意深圳市 亚辉龙生物科技股份有限公司首次公开发行股票注册的批复》（证监许可 [2021]755 号），公司向社会公众公开发行人民币普通股（A 股）4,100 万股（每 股面值人民币 1 元），并于 2021 年 5 月 17 日在上海证券交易所科创 ...

中信证券股份有限公司 关于深圳市亚辉龙生物科技股份有限公司 归还前次暂时补充流动资金的闲置募集资金并继续使用 部分闲置募集资金暂时补充流动资金的核查意见 中信证券股份有限公司（以下简称"中信证券"）为深圳市亚辉龙生物科技股 份有限公司（以下简称"公司"、"亚辉龙"）首次公开发行股票并上市的保荐人。 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则 （2023 年 8 月修订）》《上市公司监管指引第 2 号——上市公司募集资金管理 和使用的监管要求》等有关规定，对亚辉龙归还前次暂时补充流动资金的闲置募 集资金并继续使用部分闲置募集资金暂时补充流动资金事项进行了核查，并发表 如下核查意见： 一、募集资金基本情况 根据中国证券监督管理委员 2021 年 3 月 9 日核发的《关于同意深圳市亚辉 龙生物科技股份有限公司首次公开发行股票注册的批复》（证监许可[2021]755 号），公司向社会公众公开发行人民币普通股（A 股）4,100 万股（每股面值人 民币 1 元），并于 2021 年 5 月 17 日在上海证券交易所科创板上市（以下简称"本 次发行"）。本次发行的发行价格为 14.80 元/ ...

一、注册资本变更情况 公司因 2022 年限制性股票激励计划预留部分（第二批次）第一个归属期归属，新 增股份 179,400 股，已于 2024 年 1 月 30 日在中国证券登记结算有限责任公司上海分公 司办理完毕新增股份的登记手续，公司总股本由 568,129,100 股增加至 568,308,500 股， 注册资本由 56,812.91 万元增加至 56,830.85 万元。具体内容详见公司于 2024 年 2 月 1 日在上海证券交易所网站（www.sse.com.cn）披露的《关于 2022 年限制性股票激励计 划预留部分（第二批次）第一个归属期归属结果暨股份上市的公告》（公告编号： 2024-008）。 二、《公司章程》修订情况 鉴于上述事项，根据《公司法》、《证券法》和《上海证券交易所科创板股票上市 规则》等相关规定，公司拟对《公司章程》相关条款进行修订并办理工商登记变更手续。 详细内容如下： | 原文条款 | 修订前 | | 修订后 | | | --- | --- | --- | --- | --- | | 第七条 | 公司注册资本为人民币 | 56,812.91 万元。 | 公司注册资本为人 ...

证券代码：688575 证券简称：亚辉龙 公告编号：2024-014 深圳市亚辉龙生物科技股份有限公司 第三届董事会第二十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳市亚辉龙生物科技股份有限公司（以下简称"公司"）第三届董事会第二十一 次会议（以下简称"本次会议"）于 2024 年 4 月 18 日以现场加通讯方式召开，会议应 到董事 7 人，实到董事 7 人，出席董事占应出席人数的 100%。本次会议的召集、召 开程序符合《公司章程》和有关法律、法规的要求。经与会董事审议和表决，会议形 成如下决议： 表决结果：7 票同意；0 票反对；0 票弃权。 一、审议通过《关于<公司 2023 年度总经理工作报告>的议案》 本事项尚需提交股东大会审议。 公司总经理对 2023 年度开展的工作进行了总结，并将公司 2023 年度经营管理 工作向董事会进行汇报。公司经营情况详见公司于同日在上海证券交易所网站 （www.sse.com.cn）披露的《深圳市亚辉龙生物科技股份有限公司 2023 年年度报告》。 三、 ...